Evidence map›Paper›PMID 38964520›Full record

ArticleBioorganic & medicinal chemistry letters2024

Semisynthetic derivatives of the fungal metabolite eupenifeldin via targeting the tropolone hydroxy groups.

Zeinab Y Al Subeh, Herma C Pierre, Ross H Bockbrader, Robert J Tokarski, Amanda C Maldonado, Monica A Haughan, Manuel E Rangel-Grimaldo, Cedric J Pearce, Joanna E Burdette, James R Fuchs and 1 more

Abstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zeinab Y Al SubehDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan; Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, P.O. Box 26170, Greensboro, NC 27402, United States.
Herma C PierreDepartment of Chemistry and Biochemistry, University of North Carolina at Greensboro, P.O. Box 26170, Greensboro, NC 27402, United States.
Ross H BockbraderDivision of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Ohio State University, 500 W. 12(th) Ave., Columbus, OH 43210, United States.
Robert J TokarskiDivision of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Ohio State University, 500 W. 12(th) Ave., Columbus, OH 43210, United States.
Amanda C MaldonadoDepartment of Pharmaceutical Sciences, University of Illinois at Chicago, 900 S. Ashland Ave (M/C 870), Chicago, IL 60607, United States.
Monica A HaughanDepartment of Pharmaceutical Sciences, University of Illinois at Chicago, 900 S. Ashland Ave (M/C 870), Chicago, IL 60607, United States.
Manuel E Rangel-GrimaldoDepartment of Chemistry and Biochemistry, University of North Carolina at Greensboro, P.O. Box 26170, Greensboro, NC 27402, United States.
Cedric J PearceMycosynthetix, Inc., Hillsborough, NC 27278, United States.
Joanna E BurdetteDepartment of Pharmaceutical Sciences, University of Illinois at Chicago, 900 S. Ashland Ave (M/C 870), Chicago, IL 60607, United States.
James R FuchsDivision of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Ohio State University, 500 W. 12(th) Ave., Columbus, OH 43210, United States. Electronic address: fuchs.42@osu.edu.
Nicholas H OberliesDepartment of Chemistry and Biochemistry, University of North Carolina at Greensboro, P.O. Box 26170, Greensboro, NC 27402, United States. Electronic address: n_oberli@uncg.edu.

Funding

Project 3:Isolation Chemistry of Filamentous Fungi and Biological EvaluationP01CA125066 · NCI · OHIO STATE UNIVERSITY · PI JAMES R FUCHS · 2007 to 2026
$27.2M
Pilot Program CoreP30ES027792 · NIEHS · UNIVERSITY OF CHICAGO · PI Gokhan M. Mutlu, Gail S Prins · 2017 to 2026
$13.6M
Predoctoral Training: Innovative Technologies for Natural Products and Integrative Medicine ResearchT32AT008938 · NCCIH · UNIVERSITY OF NORTH CAROLINA GREENSBORO · PI Nadja B Cech, Jonathan Rodi Chekan · 2016 to 2026
$1.6M
NCCIH NIH HHS T32 AT008938NCI NIH HHS P01 CA125066NIEHS NIH HHS P30 ES027792
6 · The paper itself

Abstract

Eupenifeldin (1) is a fungal secondary metabolite possessing bis-tropolone moieties that demonstrates nanomolar cytotoxic activity against a number of cancer cell types. As a potential anticancer lead, this meroterpenoid was used to access 29 semisynthetic analogues via functionalization of the reactive hydroxy groups of the bis-tropolones. A series of ester (2-6), carbonate (7-8), sulfonate (9-16), carbamate (17-20), and ether (21-30) analogues of 1 were generated via 22 reactions. Most of these compounds were disubstituted, produced via functionalization of both of the tropolonic hydroxy moieties, although three mono-functionalized analogues (6, 8, and 24) and one tri-functionalized analogue (3) were also obtained. The cytotoxic activities of 1-30 were evaluated against human melanoma and ovarian cancer cell lines (i.e., MDA-MB-435 and OVCAR3, respectively). Ester and carbonate analogues of 1 (i.e., 2-8) maintained cytotoxicity at the nanomolar level, and the greatest improvement in aqueous solubility came from the monosuccinate analogue (6), which was acylated on the secondary hydroxy at the 11 position.

Indexed as

Antineoplastic AgentsTropoloneArylsulfonatesCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorFungiHumansMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsArylsulfonatesTropoloneBis-tropoloneEupenifeldinFungal metabolitesMeroterpenoidsSemisynthetic analogues

Identifiers

PMID38964520
PMCPMC11369961

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.